Re­struc­tured Melin­ta now wants to buy fel­low an­tibi­ot­ic mak­er Tetraphase; TA As­so­ciates mulls $500M deal for a stake in CD­MO

→ Yet an­oth­er buy­er has emerged in what is shap­ing up to be a bid­ding war for Tetraphase and its mar­ket­ed an­tibi­ot­ic. Melin­ta — a fel­low an­tibi­otics mak­er that’s fresh­ly re­struc­tured un­der Chap­ter 11 and now pri­vate­ly owned by Deer­field — is of­fer­ing to buy it all for $27 mil­lion, more than dou­ble the orig­i­nal of­fer by Acel­Rx that the Tetraphase board had rec­om­mend­ed back in March. Since then, La Jol­la has al­so pro­posed a $22 mil­lion deal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER